Efficacy of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to the prostate for intermediate- and high-risk prostate cancer

摘要

Objectives The objective of this study is to evaluate the efficacy as well as acute and late toxicities of pelvic intensity-modulated radiotherapy (BVIRT) with hypofractionated simultaneous integrated boost (SIB) to the prostate for patients with intermediate- and high-risk prostate cancer. Methods A retrospective analysis was performed of 66 patients treated definitively with pelvic SIB-DVIRT in a prospective fashion; all of whom also received androgen suppression. The IMRT plans were designed to deliver 70 Gy in 28 fractions (2.5 Gy/fraction) to the prostate while simultaneously delivering 50.4 Gy in 28 fractions (1.8 Gy/fraction) to the pelvic lymph nodes.